Zheng Quan Zhi Xing·2025-09-02 16:26Summary of Key Points Core Viewpoint - The stock of BeiGene, Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 28 to September 1, 2025, prompting a regulatory announcement regarding the situation [1]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly, with a cumulative deviation of over 30% during the specified trading days, which is classified as abnormal trading behavior according to the Shanghai Stock Exchange regulations [1]. - The company confirmed that its production and operational activities are normal, with no significant changes in the market environment or industry policies [1]. Group 2: Company Verification - The company conducted a self-examination and found no major undisclosed events that could impact stock prices, nor any media reports or market rumors that could significantly affect the stock [1]. - There were no significant events or information that should have been disclosed according to the relevant regulations, and no insider trading activities were reported among directors or senior management during the abnormal trading period [1]. Group 3: Board of Directors Statement - The Board of Directors confirmed that, apart from disclosed matters, there are no undisclosed items that could materially affect the company's stock price or related trading instruments [1].